A single intravenous infusion of an experimental CRISPR therapy called CTX310 lowered LDL cholesterol by 52.5% and triglycerides by 47.8% a year later in the highest-dose group of a 15-patient trial, Cleveland Clinic reported on August 28, 2026. The results were presented at the European Society of Cardiology congress and published the same day in the New England Journal of Medicine. Nothing was re-dosed during the follow-up, and the readings stayed flat.
The trial is small and early, and the 52.5% figure describes the top of a dose ladder rather than everyone enrolled. The durability is what drew attention.
What CTX310 edits, and where
CTX310 was developed by CRISPR Therapeutics, which also funded the study. It is delivered to the liver, where the CRISPR-Cas9 machinery disables a gene called ANGPTL3. The gene’s protein helps regulate circulating blood fats, so knocking it out lowers both LDL cholesterol and triglycerides. People born with natural loss-of-function versions of ANGPTL3 tend to have low lipids, which is the biological logic behind the target.
Because the edit is made to DNA in liver cells rather than to a protein that wears off, a single dose is meant to be permanent, in contrast with daily pills and repeated injections that must be taken indefinitely. The trial’s one-year window is the first test of whether that promise holds in people, and the plateau Nissen describes is the early evidence that it does. The reductions were visible at the first two-month measurement and did not drift back toward baseline through month 12, which is the pattern a permanent edit would produce and a wearing-off drug would not. The company’s release reports that at the highest dose, 0.8 mg/kg, ANGPTL3 protein fell a mean of 79%, triglycerides a mean of 48% and LDL a mean of 53%.
Fifteen patients across five dose levels
The Phase 1a study enrolled 15 adults with lipid disorders that resisted standard treatment, and gave them ascending doses from 0.1 to 0.8 mg/kg in an open-label design. According to the Cleveland Clinic newsroom release, the participants fell into groups that included homozygous familial hypercholesterolemia, severe hypertriglyceridemia, heterozygous familial hypercholesterolemia and mixed dyslipidemias, and all completed at least a year of follow-up.
Cleveland Clinic’s clinician-facing summary gives the top-dose figures in full: ANGPTL3 down 78.6%, LDL cholesterol down 52.5%, triglycerides down 47.8% and apolipoprotein B down 37.2% at one year. Only the highest-dose group produced the 52.5% figure, and the release does not say how many of the 15 patients that group held. Doses rose in steps so that safety could be checked at each level before the next group was treated.
Dr. Luke Laffin, the Cleveland Clinic cardiologist who led the work, called the durability “impressive.” Dr. Steven Nissen, the institution’s chief academic officer for heart, vascular and thoracic care, put it in terms of the curves: “The good news is that the levels of ANGPTL3 and lipids remained low and flat through the full year.” Laffin also noted there were “no serious safety events related to CTX310,” and both physicians framed the result as a durability signal, not an efficacy verdict: a Phase 1 is designed to find out whether a dose is safe and whether the biology behaves as predicted, and on those two questions the one-year data came back clean, with the larger and longer questions still ahead.
The design limits what can be claimed. The study was open-label, so patients and investigators knew a real product was being infused, and there was no placebo arm. Each participant’s lipids after treatment were compared with that same person’s baseline, which is a reasonable yardstick for a gene edit that is not expected to reverse on its own, but it leaves no control group to absorb changes in diet, other medication or ordinary variation in cholesterol readings across twelve months. CRISPR Therapeutics AG funded the trial and employs the chief medical officer, Naimish Patel, who described the aim as “one-time treatments for cardiometabolic diseases.”
Safety findings and what a Phase 1 cannot show
No dose-limiting toxicities or serious adverse events related to CTX310 occurred during follow-up. The company’s release does record milder events: one allergic reaction that resolved with supportive care and three Grade 2 infusion-related reactions, with no liver enzyme elevations during extended follow-up. Liver safety is the watched variable.
A trial of 15 people followed for a year cannot answer the questions that decide whether a drug reaches clinics: whether unintended edits appear elsewhere in the genome, whether effects hold over decades, and whether cardiovascular events fall along with the lipid numbers. Lower LDL is a surrogate marker. No outcome trial exists yet for this therapy.
The regulatory clock reflects that uncertainty. Cleveland Clinic says the FDA has requested that participants be monitored for 15 years, and the agency’s long-term follow-up guidance, issued in January 2020, asks sponsors to assess when such observation is needed. The ScienceDaily repost of September 25 adds no new data to the August results.
Next comes a Phase 1b study testing a fixed flat dose in specific patient groups, with an update from CRISPR Therapeutics expected in the second half of 2026, focused on severe hypertriglyceridemia. The NEJM letter on the one-year durability of CTX310 is the record against which that update will be judged.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
More from Morning Overview
- A recalled pill hid a stimulant dose linked to heart attacks and death
- Four U.S. startups fired up their first small nuclear reactors, aiming to power AI data centers on-site
- Card skimmers hidden on gas pumps and ATMs are draining accounts, and here’s the tell
- Doctors warn a silent liver disease now affects one in three American adults
